PURPOSE OF REVIEW: Therapies that increase functional β-cell mass may be the best long-term treatment for diabetes. Significant resources are devoted toward this goal, and progress is occurring at a rapid pace. Here, we summarize recent advances relevant to human β-cell regeneration. RECENT FINDINGS: New β-cells arise from proliferation of pre-existing β-cells or transdifferentiation from other cell types. In addition, dedifferentiated β-cells may populate islets in diabetes, possibly representing a pool of cells that could redifferentiate into functional β-cells. Advances in finding strategies to drive β-cell proliferation include new insight into proproliferative factors, both circulating and local, and elements intrinsic to the β-cell, such as cell cycle machinery and regulation of gene expression through epigenetic modification and noncoding RNAs. Controversy continues in the arena of generation of β-cells by transdifferentiation from exocrine, ductal, and alpha cells, with studies producing both supporting and opposing data. Progress has been made in redifferentiation of β-cells that have lost expression of β-cell markers. SUMMARY: Although significant progress has been made, and promising avenues exist, more work is needed to achieve the goal of β-cell regeneration as a treatment for diabetes.
PURPOSE OF REVIEW: Therapies that increase functional β-cell mass may be the best long-term treatment for diabetes. Significant resources are devoted toward this goal, and progress is occurring at a rapid pace. Here, we summarize recent advances relevant to human β-cell regeneration. RECENT FINDINGS: New β-cells arise from proliferation of pre-existing β-cells or transdifferentiation from other cell types. In addition, dedifferentiated β-cells may populate islets in diabetes, possibly representing a pool of cells that could redifferentiate into functional β-cells. Advances in finding strategies to drive β-cell proliferation include new insight into proproliferative factors, both circulating and local, and elements intrinsic to the β-cell, such as cell cycle machinery and regulation of gene expression through epigenetic modification and noncoding RNAs. Controversy continues in the arena of generation of β-cells by transdifferentiation from exocrine, ductal, and alpha cells, with studies producing both supporting and opposing data. Progress has been made in redifferentiation of β-cells that have lost expression of β-cell markers. SUMMARY: Although significant progress has been made, and promising avenues exist, more work is needed to achieve the goal of β-cell regeneration as a treatment for diabetes.
Authors: Shay Porat; Noa Weinberg-Corem; Sharona Tornovsky-Babaey; Rachel Schyr-Ben-Haroush; Ayat Hija; Miri Stolovich-Rain; Daniela Dadon; Zvi Granot; Vered Ben-Hur; Peter White; Christophe A Girard; Rotem Karni; Klaus H Kaestner; Frances M Ashcroft; Mark A Magnuson; Ann Saada; Joseph Grimsby; Benjamin Glaser; Yuval Dor Journal: Cell Metab Date: 2011-04-06 Impact factor: 27.287
Authors: N Poungvarin; J K Lee; V K Yechoor; M V Li; T Assavapokee; P Suksaranjit; J J Thepsongwajja; P K Saha; K Oka; L Chan Journal: Diabetologia Date: 2012-03-03 Impact factor: 10.122
Authors: Yan Wang; Fabiana Quagliarini; Viktoria Gusarova; Jesper Gromada; David M Valenzuela; Jonathan C Cohen; Helen H Hobbs Journal: Proc Natl Acad Sci U S A Date: 2013-09-16 Impact factor: 11.205
Authors: Yoshifumi Saisho; Alexandra E Butler; Erica Manesso; David Elashoff; Robert A Rizza; Peter C Butler Journal: Diabetes Care Date: 2012-08-08 Impact factor: 19.112
Authors: Haytham Aly; Nidhi Rohatgi; Connie A Marshall; Tiffani C Grossenheider; Hiroyuki Miyoshi; Thaddeus S Stappenbeck; Scot J Matkovich; Michael L McDaniel Journal: PLoS One Date: 2013-06-12 Impact factor: 3.240
Authors: Matthew M Rankin; Christopher J Wilbur; Kimberly Rak; Emily J Shields; Anne Granger; Jake A Kushner Journal: Diabetes Date: 2013-01-24 Impact factor: 9.461
Authors: James E Schwob; Woochan Jang; Eric H Holbrook; Brian Lin; Daniel B Herrick; Jesse N Peterson; Julie Hewitt Coleman Journal: J Comp Neurol Date: 2016-09-27 Impact factor: 3.215